Safety and Effectiveness of Paclitaxel Drug-Coated Devi Revascularization: Insights From VOYAGER PAD

Journal of the American College of Cardiology

78, 1768-1778

DOI: 10.1016/j.jacc.2021.08.052

Citation Report

#	Article	IF	Citations
1	Antiproliferative Device Coatings: Efficacy Without Adverse Drug Effect?. Journal of the American College of Cardiology, 2021, 78, 1779-1781.	12.0	0
2	Interventionelle Therapie der peripheren arteriellen Verschlusskrankheit. Der Internist, 2022, 63, 584-590.	0.7	4
3	Update From the Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. Circulation: Cardiovascular Interventions, 2022, 15, e012074.	6.2	21
4	Safety and Efficacy of All Comers Treated With a Paclitaxel Coated Balloon for Below Knee Intervention. European Journal of Vascular and Endovascular Surgery, 2022, 64, 516-525.	3.2	9
5	State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100439.	2.3	14
6	Algorithm of Femoropopliteal Endovascular Treatment. Medicina (Lithuania), 2022, 58, 1293.	3.3	7
7	Low-Dose vs High-Dose Paclitaxel-Coated Balloons for Femoropopliteal Lesions: 2-Year Results From the COMPARE Trial. JACC: Cardiovascular Interventions, 2022, 15, 2093-2102.	5.0	41
8	Outcome After Revascularization With Paclitaxel-Coated Devices in Patients With Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2023, 77, 1742-1750.	3.4	11
9	Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison With the Voyager Pad Endovascular Cohort. Journal of Cardiovascular Development and Disease, 2023, 10, 115.	2.9	2
10	Evidenzbasierte Gefäßchirurgie. Evidenzbasierte Chirurgie, 2022, .	0.0	2
11	Trattamento endovascolare delle lesioni ateromatose del segmento femoropopliteo. EMC - Tecniche Chirurgiche Vascolare, 2023, 28, 1-12.	0.0	0
12	Limb Salvage and Survival in Chronic Limb-Threatening Ischemia: The Need for a Fast-Track Team-Based Approach. Journal of Clinical Medicine, 2023, 12, 6081.	3.8	56
13	A Slice in the Right Direction – Novel Use of Directional Atherectomy for Treatment of Upper Limb Vascular Insufficiency and Concurrent Diagnosis. Indian Journal of Vascular and Endovascular Surgery, 2023, 10, 148.	0.3	0
14	Limb Preservation for the Vascular Specialist. , 2023, .		2
15	Mortality in Randomised Controlled Trials Using Paclitaxel-Coated Devices for Femoropopliteal Interventional Procedures: An Updated Patient-Level Meta-Analysis. Lancet, The, 2023, 402, 1848-1856.	96.9	58
16	A Unique Mechanism of Restenosis After Drug-Coated Balloon in Peripheral Artery: Insight From Optical Frequency Domain Imaging. Cardiovascular Revascularization Medicine, 2024, 62, 119-122.	1.6	4
17	Evidence-Based Therapy in Vascular Surgery. , 2023, .		0
18	Long-Term Follow-Up and Mortality Rate of Patients of the Randomized Freeway Stent Study. CardioVascular and Interventional Radiology, 2024, 47, 186-193.	2.3	3

#	Article	IF	Citations
19	“Evolution of Drug-Coated Devices for the Treatment of Chronic Limb Threatening Ischemia”. Annals of Vascular Surgery, 2024, 0, 76-83.	1.8	7
20	Interventional Treatment of PAD: Drug-Coated Balloons and Stents. , 2024, .		0
21	Exploring the Potential of MIM-Manufactured Porous NiTi as a Vascular Drug Delivery Material. Annals of Biomedical Engineering, 2024, 52, 1-17.	5.5	2
22	Drug-Eluting Devices for Lower Limb Peripheral Arterial Disease. EuroIntervention, 2024, 20, e1136-e1153.	4.9	31
23	Quantifying Patients’ Preferences on Tradeoffs Between Mortality Risk and Reduced Need for Target Vessel Revascularization for Claudication. Vascular Medicine, 2024, 29, 675-683.	2.3	3
24	Impact of Lesion Preparation-Induced Calcified Plaque Defects in Vascular Intervention for Atherosclerotic Disease: In Silico Assessment. Biomechanics and Modeling in Mechanobiology, 2025, 24, 1-14.	3.1	4
25	Femoropopliteal Interventions for Peripheral Artery Disease: A Review of Current Evidence and Future Directions. Interventional Cardiology Clinics, 2025, 14, 243-256.	1.1	3
26	Efficacy of Paclitaxel-Coated Versus Uncoated Balloon Angioplasty for Revascularization of Coronary In-Stent Restenosis: A Meta-Analysis and Metaregression. Coronary Artery Disease, 2025, 36, 569.	2.2	0
27	Antiproliferative Endovascular Drug Technology Is Associated With Fewer Major Reinterventions After Femoropopliteal Interventions for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2025, 82, 1375-1382.	3.4	5
28	Predictors of Restenosis After Drug-Coated Balloon Angioplasty for Femoropopliteal Chronic Total Occlusion Lesions. CVIR Endovascular, 2025, 8, 92.	2.5	1
29	SAFE-PAD: Leveraging Claims Data for the Public Good. European Heart Journal, 2026, 47, 2104-2106.	14.7	1
30	Emerging Sirolimus-Based Drug-Coated Technologies for Femoropopliteal Disease: A Systematic Review. Journal of Endovascular Therapy, 2026, .	2.1	1
31	Tuning the Intrinsic Bioactivity of Porous NiTi Alloys via Microstructural Architecture to Control Vascular Remodeling. Next Materials, 2026, 11, 101954.	3.5	0
32	Pharmacokinetics, Safety, and Exploratory 12-Month Clinical Follow-Up of a Novel BIOtorcin™-Coated Balloon for Femoropopliteal Artery Disease: The BRight PK Study. Biomedicines, 2026, 14, 2359.	4.9	0